Related Experiment Video
Updated: Aug 14, 2026
10:04
Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
Published on: August 1, 2025
Antigen presentation requirements for effective cDC1-based cancer immunotherapy
Josué E Pineda1,2, Tomoyuki Minowa1, Li Shen3
1Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Journal of Immunology (Baltimore, Md. : 1950)
|August 13, 2026
Summary
Type 1 conventional dendritic cells (cDC1s) vaccination shows promise for cancer treatment. Both MHC-I and MHC-II antigen presentation by vaccine cDC1s, along with host cDC1s, are crucial for effective antitumor immunity.
Area of Science:
- Immunology
- Cancer Biology
- Cellular Immunology
Background:
- Type 1 conventional dendritic cells (cDC1s) are vital for antitumor immunity, with their tumor abundance correlating with better patient outcomes.
- Previous studies demonstrated that vaccination with in vitro-derived cDC1s can induce durable tumor control in preclinical models.
- The precise immunological mechanisms driving the efficacy of cDC1 vaccination remain incompletely understood.
Purpose of the Study:
- To investigate whether in vitro-derived cDC1s mirror tumor-infiltrating dendritic cell (DC) populations.
- To determine the contribution of MHC-I and MHC-II antigen presentation to cDC1-mediated tumor control after vaccination.
- To elucidate the role of host cDC1s in supporting the efficacy of in vitro-derived cDC1 vaccination.
Main Methods:
- Transcriptional profiling of cDC1s under homeostasis and following stimulation with poly dI:dC.
- Comparative analysis of in vitro-derived cDC1s with tumor-infiltrating DC populations.
- Assessment of tumor control in mice with deficiencies in MHC-I, MHC-II, or endogenous cDC1s (Irf8+/–32–/– mice).
Main Results:
- In vitro-derived cDC1s closely resemble steady-state tumor-infiltrating cDC1s and, upon stimulation, resemble CCR7+ tumor-infiltrating DCs.
- Both MHC-I and MHC-II antigen presentation by vaccine cDC1s are essential for robust antitumor responses.
- Coexpression of MHC-I and MHC-II on the same cDC1 is necessary for optimal vaccine efficacy.
- Host cDC1s play a significant role in supporting the effectiveness of in vitro-derived cDC1 vaccination.
Conclusions:
- Effective antitumor immunity elicited by cDC1 vaccination relies on MHC-I and MHC-II antigen presentation by the vaccine-delivered cDC1s.
- The presence and function of host cDC1s are also critical for maximizing the therapeutic benefits of cDC1 vaccination.
- These findings highlight the importance of both vaccine-derived and host immune cells for successful cancer immunotherapy strategies involving cDC1s.
Related Concept Videos
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
01:30Cancer Vaccines
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:26Antigens Involved in Adaptive Immunity
An antigen is any substance the immune system identifies as foreign and potentially harmful to the body, prompting an immune response. Antigens have two functional properties: immunogenicity and reactivity. Immunogenicity is the ability of an antigen to stimulate a specific immune response. At the same time, reactivity describes the antigen's ability to react with the cells and antibodies produced in response to it.
Complete Antigens
Complete antigens possess both immunogenicity and reactivity.
Complete Antigens
Complete antigens possess both immunogenicity and reactivity.
01:22T Cell Activation and Clonal Selection
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Naive T cells that have not yet encountered an antigen express two primary CD...
01:22Antigen Presenting Cells
The immune system is a complex network of cells and molecules that protects the body from foreign invaders. T cells, a type of white blood cell, play a crucial role in this process. They recognize and attack foreign substances, such as pathogens, that enter the body.
T cells require the help of antigen-presenting cells (APCs), which process foreign antigens into smaller fragments that can be recognized by T cells. These APCs are highly specialized cells that efficiently internalize antigens...
T cells require the help of antigen-presenting cells (APCs), which process foreign antigens into smaller fragments that can be recognized by T cells. These APCs are highly specialized cells that efficiently internalize antigens...